Name: Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Administration
Published: 2026-09-17T18:16:06-04:00

Product information and disease description Product description Product information Dosing and administration

Administration

3 evidence topics · 4 sources

In-office intravitreal injection

“DURAVYU is delivered via a standard intravitreal injection in the physician's office, similar to current practice with FDA approved anti-VEGF treatments.” (opens the source at this quote in a new tab)

Pre-loaded applicator and 22-gauge needle (phase 2)

“The drug delivery system is placed into a one-time-use siliconized needle attached to an applicator delivery system. The drug product is sterilized after packaging and prior to distribution. In subject, the needle is inserted through the pars plana and the insert is injected into the vitreous.” (opens the source at this quote in a new tab)
“EYP-1901 will be administered to the study eye by a single injection through the pars plana using a pre-loaded applicator with a 22-gauge needle.” (opens the source at this quote in a new tab)

Injector performance in phase 1 and further injector development

“Investigators experienced difficulties with the injector related to the advancement of the plunger as it pushed the 3 inserts (1030 μg each) through the needle.” (opens the source at this quote in a new tab)
“The injector issues that caused the deviation have been resolved in the subsequent phase II DAVIO 2 trial, and the device continues to be in development.” (opens the source at this quote in a new tab)

“for a new injector designed for administration of Durasert” (opens the source at this quote in a new tab)

Needle gauge and injector used in phase 3

No evidence found.